 Connection
Elaine Lam to Prostatic Neoplasms, Castration-Resistant
This is a "connection" page, showing publications Elaine Lam has written about Prostatic Neoplasms, Castration-Resistant.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.468 |
|
|
|
-
Stein MN, Fong L, Tutrone R, Mega A, Lam ET, Parsi M, Vangala S, Gutierrez AA, Haas NB. ADXS31142 Immunotherapy ? Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. Oncologist. 2022 06 08; 27(6):453-461.
Score: 0.199
-
Kessler ER, Gao D, Flaig TW, Breaker K, Wold M, Wacker M, Lam ET. Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Ann Oncol. 2017 03 01; 28(3):668.
Score: 0.138
-
Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, B?gemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Hou?d? N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. J Clin Oncol. 2016 09 01; 34(25):3005-13.
Score: 0.132
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|